Literature DB >> 8083863

Correlation between beta- and alpha-adrenergic receptor concentrations in human placenta.

G Falkay1, K Melis, L Kovács.   

Abstract

alpha 2- and beta-adrenergic receptors in human placental membranes have been investigated using the radioligands [3H]-RX 821002 and [3H]-dihydroalprenolol, respectively. The specific binding of the alpha 2-adrenoceptor antagonist RX 821002 confirms the presence of an alpha 2-adrenoceptor in the human placenta, which has been characterized previously with [3H]-rauwolscine. The major finding presented here is a correlation between the alpha 2- and beta-adrenergic receptor concentrations (r = 0.765) in the human placenta at term. It is suggested that the alpha 2/beta adrenoceptor balance may play an important role in regulation of the vascular bed of the placenta. Determination of the alpha 2/beta ratio may help towards an understanding of the contractility of the placental vascular muscles.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083863     DOI: 10.3109/10799899409066030

Source DB:  PubMed          Journal:  J Recept Res        ISSN: 0197-5110


  3 in total

1.  Human Placenta Expresses α2-Adrenergic Receptors and May Be Implicated in Pathogenesis of Preeclampsia and Fetal Growth Restriction.

Authors:  Hanaa K B Motawea; Maqsood A Chotani; Mehboob Ali; William Ackerman; Guomao Zhao; Amany A E Ahmed; Catalin S Buhimschi; Irina A Buhimschi
Journal:  Am J Pathol       Date:  2018-09-29       Impact factor: 4.307

2.  In-vitro study of the effect of anti-hypertensive drugs on placental hormones and angiogenic proteins synthesis in pre-eclampsia.

Authors:  Subrata Gangooly; Shanthi Muttukrishna; Eric Jauniaux
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

3.  Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders.

Authors:  Asma Khalil; Shanthi Muttukrishna; Kevin Harrington; Eric Jauniaux
Journal:  PLoS One       Date:  2008-07-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.